Background: The platelet-derived chemokine platelet factor 4 (PF4) promotes blood coagulation and serves as a chemoattractant for immune cells. Recently PF4 has been shown to inhibit HIV-1 infection in vitro at concentrations less than 0.5μM. However, despite plasma and local tissue concentrations of PF4 ranging from 0.25nM to 10μM, HIV is able to successfully replicate and escape the inhibitory effects of PF4 in vivo. The mechanism of this discordance remains unclear. Here, we demonstrate that the inhibitory effects of PF4 are limited to a narrow concentration range, corresponding to the predominance of a monomeric state. At concentrations of greater than 1μM, PF4 multimerizes and viral infection in vitro is enhanced. Methodology: Wildtype and mutant PF4s with distinct oligomeric properties were tested for their ability to inhibit viral infection in vitro. We examined the ability of HIV-1 pseudotyped viruses expressing the envelope glycoprotein from CCR5- and CXCR4-using HIV-1, MLV, influenza (H5N1), and VSV-G to infect cell lines and primary human CD4+ T cells in the presence of increasing amounts of either wildtype or mutant PF4. Infection data was compared using t-tests and Fisher’s exact tests. Results: All HIV-1 Envs (n = 24) were inhibited (mean = 65%, SD = 30) by PF4 (<1μM) independent of coreceptor tropism. VSV-G and MLV were also inhibited, while influenza H5N1 pseudoviruses were resistant to PF4. Surprisingly, the inhibitory effects of PF4 waned at concentrations greater than 1μM, above which viral entry was enhanced. Moreover, at concentrations above 1μM of the PF4 mutant K50E, which disrupts the formation of tetramers, we observed approximately 70% inhibition of viral infection. This was in contrast to the 2- to 5-fold enhancement observed with the wildtype PF4 at the same concentration. Chemical crosslinking was used to confirm differences in the oligomeric state of the wildtype and mutant PF4s at the different concentrations tested. Conclusions: While PF4 inhibits diverse HIV-1 strains in its monomeric state, we demonstrate that it enhances infection when it exists as a tetramer. Since PF4 exists in a dynamic equilibrium, with tetramers predominating at physiologic levels, we conclude that the in vitro inhibitory effects of PF4 are less likely to predominate at physiologic PF4 concentrations. A more detailed understanding of how PF4 modulates viral infection may reveal new insights into viruschemokine interactions that could inform novel therapeutic interventions.